Literature DB >> 34743189

Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.

Severine Cathelin1, David Sharon2, Amit Subedi1, Dan Cojocari2, Darren C Phillips2, Joel D Leverson3, Kyle J MacBeth4, Brandon Nicolay5, Rohini Narayanaswamy5, Sebastien Ronseaux5, Guowen Liu5, Steven M Chan6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34743189     DOI： 10.1038/s41375-021-01468-y

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  1 in total

1.  Regulation and function of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells.

Authors:  A Benito; D Grillot; G Nuñez; J L Fernández-Luna
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307
  1 in total
  2 in total

Review 1.  IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.

Authors:  Remco J Molenaar; Johanna W Wilmink
Journal:  J Histochem Cytochem       Date:  2022-01       Impact factor: 4.137

2.  Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.

Authors:  Sangeetha Venugopal; Koichi Takahashi; Naval Daver; Abhishek Maiti; Gautam Borthakur; Sanam Loghavi; Nicholas J Short; Maro Ohanian; Lucia Masarova; Ghayas Issa; Xuemei Wang; Bueso-Ramos Carlos; Musa Yilmaz; Tapan Kadia; Michael Andreeff; Farhad Ravandi; Marina Konopleva; Hagop M Kantarjian; Courtney D DiNardo
Journal:  Blood Cancer J       Date:  2022-01-25       Impact factor: 9.812
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.